Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept

Targeted Oncology

Volumn 8, Issue 2, 2013, Pages 117-125

  Shonka, Nicole ^a   Piao, Yuji ^b   Gilbert, Mark ^b   Yung, Alfred ^b   Chang, Susan ^c   Deangelis, Lisa M ^d   Lassman, Andrew B ^e   Liu, Jun ^b   Cloughesy, Timothy ^f   Robins, H Ian ^g   Lloyd, Rita ^g   Chen, Alice ^h   Prados, Michael ^c   Wen, Patrick Y ⁱ   Heymach, John ^b   De Groot, John ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Aflibercept; Cytokines; Glioblastoma; Toxicity; VEGF

Indexed keywords

AFLIBERCEPT; ANGIOGENIC FACTOR; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 3;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BLEEDING; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ERUPTION; DRUG INDUCED DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; GLIOBLASTOMA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; PERICARDITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; RECURRENT CANCER; SIDE EFFECT; THROMBOEMBOLISM;

ADULT; AGED; ANGIOGENIC PROTEINS; BRAIN NEOPLASMS; COHORT STUDIES; CYTOKINES; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; PROPORTIONAL HAZARDS MODELS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878798318     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0254-0     Document Type: Article

References (34)

1. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28(17):2817-2823
2. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-4740
3. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740-745
4. Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP, Jain RK (2011) Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value. Clin Cancer Res 17(4):918-927. doi: 10.1158/1078-0432.CCR-10-0515
5. Okunieff P, Chen Y, Maguire DJ, Huser AK (2008) Molecular markers of radiation-related normal tissue toxicity. Cancer Metastasis Rev 27(3):363-374. doi: 10.1007/s10555-008-9138-7
6. Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN (1995) A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33(1):99-109
7. De Jaeger K, Seppenwoolde Y, Kampinga HH, Boersma LJ, Belderbos JS, Lebesque JV (2004) Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58(5):1378-1387. doi: 10.1016/j.ijrobp.2003.09.078
8. Menard C, Johann D, Lowenthal M, Muanza T, Sproull M, Ross S, Gulley J, Petricoin E, Coleman CN, Whiteley G, Liotta L, Camphausen K (2006) Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res 66(3):1844-1850. doi: 10.1158/0008-5472.CAN-05-3466
9. Kovacs CJ, Daly BM, Evans MJ, Johnke RM, Lee TK, Karlsson UL, Allison R, Eaves GS, Biggs LM (2003) Cytokine profiles in patients receiving wide-field + prostate boost radiotherapy (xRT) for adenocarcinoma of the prostate. Cytokine 23(6):151-163
10. Christensen E, Pintilie M, Evans KR, Lenarduzzi M, Menard C, Catton CN, Diamandis EP, Bristow RG (2009) Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clin Cancer Res 15(17):5576-5583. doi: 10.1158/1078-0432.CCR-09-0245
11. Hartsell WF, Scott CB, Dundas GS, Mohiuddin M, Meredith RF, Rubin P, Weigensberg IJ (2007) Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03. Am J Clin Oncol 30(4):368-376. doi: 10.1097/01.coc.0000260950.44761.74
12. Wichers M, Maes M (2002) The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 5(4):375-388. doi: 10.1017/S1461145702003103
13. Ryan JL, Carroll JK, Ryan EP, Mustian KM, Fiscella K, Morrow GR (2007) Mechanisms of cancer-related fatigue. Oncologist 12(Suppl 1):22-34. doi: 10.1634/theoncologist.12-S1-22
14. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran WJ Jr (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60(3):853-860
15. Daigle JL, Hong JH, Chiang CS, McBride WH (2001) The role of tumor necrosis factor signaling pathways in the response of murine brain to irradiation. Cancer Res 61(24):8859-8865
16. Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE (2007) The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 21(4):413-427. doi: 10.1016/j.bbi.2006. 11.004
17. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jurgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C (2007) Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25(21):3045-3054. doi: 10.1200/JCO.2006.07.2066
18. Rixe O, Billemont B, Izzedine H (2007) Hypertension as a predictive factor of sunitinib activity. Ann Oncol 18(6):1117
19. Rixe O, Dutcher J, Motzer R, Wilding G, Stadler W, Kim S, Tarazi J, Rosbrook B, Rini B (2008) Association between diastolic blood pressure >90 mmHg and efficacy in patients with metastatic renal cell carcinoma receiving axitinib. Ann Oncol 19(8):189
20. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27(27):4462-4468. doi: 10.1200/JCO.2008.21.7034
21. Rini B, Schiller J, Fruehauf J, Cohen E, Tarazi J, Rosbrook B, Ricart A, Olszanski A, Kim S, Spano J (2008) Association of diastolic blood pressure (dBP) >=90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). J Clin Oncol 26(15):3543
22. Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim S, Rixe O (2011) Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res 17(23):7462-7469. doi: 10.1158/1078-0432.CCR-11-0534
23. Riely G, Miller V (2007) Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res 15(2):s4623-s4627
24. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP (2010) Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28(2):207-214. doi: 10.1200/JCO.2009.22.9237
25. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY (2011) Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 29(19):2689-2695. doi: 10.1200/JCO.2010.34.1636
26. de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV (2011) Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res 17(14):4872-4881. doi: 10.1158/1078-0432.CCR-11-0271
27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol 28(2):99-105
28. Shamay Y, Paulin D, Ashkenasy G, David A (2009) E-selectin binding peptide-polymer-drug conjugates and their selective cytotoxicity against vascular endothelial cells. Biomaterials 30(32):6460-6468. doi: 10.1016/j.biomaterials.2009.08.013
29. Wynn TA (2003) IL-13 effector functions. Annu Rev Immunol 21:425-456. doi: 10.1146/annurev.immunol.21.120601.141142
30. Saito A, Okazaki H, Sugawara I, Yamamoto K, Takizawa H (2003) Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch Allergy Immunol 132(2):168-176. doi: 73718
31. Van Cutsem E TJ, Lakomy R (2011) Intravenous aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262-VELOUR) Ann Oncol 22
32. Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK (2011) Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 12(12):1109-1117. doi: 10.1016/S1470-2045(11)70244-3
33. Colombo N, Mangili G, Mammoliti S, Kalling M, Tholander B, Sternas L, Buzenet G, Chamberlain D (2012) A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol 125(1):42-47. doi: 10.1016/j.ygyno.2011.11.021
34. Zhu AX, Duda DG, Sahani DV, Jain RK (2009) Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J 15(4):263-268. doi: 10.1097/PPO.0b013e3181af5e35